Dr. Nancy Nixon is a medical oncologist at the Tom Baker Cancer Centre and an Assistant Professor at the University of Calgary. She specializes in treatment of breast cancer, and is currently the Southern Alberta tumour team lead. She received a degree in biochemistry with honours from the University of Calgary in 2008 prior to medical school which she completed in 2011. She did her internal medicine and medical oncology specialization training in Calgary, finishing in 2016. In 2017, Dr. Nixon completed a clinical and research fellowship in breast cancer under the supervision of Dr. Sunil Verma. In 2017 she received an Early Career Research Program Award from the Canadian Institute of Health Research, and was featured in the Alberta Cancer Foundation’s LEAP magazine for her research focusing on patient priorities in cancer research. Dr. Nixon is also involved with translational research studies at the University of Calgary examining biomarkers for tumour response to treatment and immune therapies. Apart from her clinical and research duties Dr. Nixon is also team captain for the Tom Baker Cancer Conquerors in the Alberta Ride to Conquer Cancer, who have raised close to $1 million in research funds for the Tom Baker since 2016.
Area of Focus
Summary of Research
- Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges. June 2018 Current Oncology (in editing) Vol 25 (Supp. 1)
- Nixon NA, Hannouf M, Verma S. The evolution of biosimilars in oncology with a focus on trastuzumab. June 2018 Current Oncology (in editing) Vol 25 (Supp. 1) pg S171-179
- Nixon NA, Spackman E, Clement F, Verma S, Manns B. Cost-effectiveness of symptom monitoring with patient-reported outcomes during routine cancer treatment. Journal of Cancer Policy. 2017 Dec 29 pg 32-36 doi.org/10.1016/j.jcpo.2017.12.001
- Nixon NA, Hannouf M, Verma S. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer. European Journal of Cancer. 2017 Oct 26 pg 72-81 org/10.1016/j.ejca.2017.10.037
Area Of Focus
Summary Of Research
- Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges. June 2018 Current Oncology (in editing) Vol 25 (Supp. 1)
- Nixon NA, Hannouf M, Verma S. The evolution of biosimilars in oncology with a focus on trastuzumab. June 2018 Current Oncology (in editing) Vol 25 (Supp. 1) pg S171-179
- Nixon NA, Spackman E, Clement F, Verma S, Manns B. Cost-effectiveness of symptom monitoring with patient-reported outcomes during routine cancer treatment. Journal of Cancer Policy. 2017 Dec 29 pg 32-36 doi.org/10.1016/j.jcpo.2017.12.001
- Nixon NA, Hannouf M, Verma S. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer. European Journal of Cancer. 2017 Oct 26 pg 72-81 org/10.1016/j.ejca.2017.10.037